Table 5 Treatment received during the course of the disease
Treatment received | 3 Years of age and below at onset n = 19 | Above 3 years of age at onset n = 59 | Total patients | p-value |
|---|---|---|---|---|
Plaquenil | 1 (5%) | 17 (29%) | 78 | 0.035 |
♦ Immunosuppressant | 3 (16%) | 16 (27%) | 78 | 0.323 |
IVIG | 3 (16%) | 17 (29%) | 78 | 0.27 |
Rituximab | 0 (none) | 3 (5%) | 78 | - |
• Duration in months of methotrexate therapy | n=13 | n = 48 | 78 | - |
Mean = 24.31 | Mean = 35.17 | |||
St Dev = 15.22 | St Dev = 27.20 | |||
Median = 23.00 | Median = 26.00 | |||
Range = 1 to 51 | Range = 4 to 124 | |||
Mode = 12 | Mode = 17, 25 | |||
• Duration in months of oral prednisolone/prednisone therapy | n = 18 | n = 55 | 78 | - |
Mean = 16.89 | Mean = 33.33 | |||
St Dev = 13.62 | St Dev = 27.62 | |||
Median = 19 | Median = 23 | |||
Range = 1 to 50 | Range = 4.5-151 | |||
Mode = 19 | Mode = 14, 15, 21, 36 | |||
♦ Non-methotrexate immunosuppressant: anti-tumor necrosis factor biologics, mycophenolate mofetil, cyclosporine and cyclophosphamide | ||||